Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-30.37%
0%
-30.37%
6 Months
-42.59%
0%
-42.59%
1 Year
-54.81%
0%
-54.81%
2 Years
-70.48%
0%
-70.48%
3 Years
-60.26%
0%
-60.26%
4 Years
-81.55%
0%
-81.55%
5 Years
-84.34%
0%
-84.34%
Optibiotix Health Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-3.01%
EBIT Growth (5y)
-11.81%
EBIT to Interest (avg)
-1.71
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.09
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
37.67%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.34
EV to EBIT
-3.78
EV to EBITDA
-4.10
EV to Capital Employed
1.40
EV to Sales
8.66
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-37.03%
ROE (Latest)
-2.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
0.50
2.20
-77.27%
Operating Profit (PBDIT) excl Other Income
-2.30
-1.10
-109.09%
Interest
0.00
0.00
Exceptional Items
-8.00
0.00
Consolidate Net Profit
2.60
6.30
-58.73%
Operating Profit Margin (Excl OI)
-5,446.40%
-617.00%
-482.94%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is -77.27% vs 46.67% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is -58.73% vs 8.62% in Dec 2021
About Optibiotix Health Plc 
Optibiotix Health Plc
Pharmaceuticals & Biotechnology
Optibiotix Health Plc is a life sciences company developing a range of products to modify the human microbiome. The Company's principal activity is research and development into microbiome modulators. It operates in UK segment. The Company has a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is operated by its OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology. Its Optiscreen is a screening and optimization technology platform designed to identify microbes within the human microbiome with metabolic pathways, which can interact with human physiological processes. Its OptiBiotic is a platform technology, which generates compounds and screens them for their ability to modulate the human microbiome and its microbial end products. Its platforms are applicable across a range of other human diseases.
Company Coordinates 
Company Details
Innovation Centre, Innovation Way , HESLINGTON None : YO10 5DG
Registrar Details






